Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | PRKCI | P41743 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | GPR68 | Q15743 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15498628 | 0.84 | PRKCI (0.55) | ALDH1A1HSD17B10PRKCIFYNHTR1A | |
| SCHEMBL3790240 | 0.83 | ALDH1A1 (0.54) | ALDH1A1HSD17B10HTR7L3MBTL1ENPP2 | |
| SCHEMBL4701513 | 0.81 | ALDH1A1 (0.52) | ALDH1A1HSD17B10HTR7L3MBTL1LRRK2 | |
| SCHEMBL393770 | 0.80 | ALDH1A1 (0.60) | ALDH1A1HSD17B10L3MBTL1ADORA3ADORA2A | |
| SCHEMBL3786505 | 0.80 | ALDH1A1 (0.50) | ALDH1A1HSD17B10PRKCIHTR1AGPR68 | |
| SCHEMBL358974 | 0.80 | PRKCI (0.44) | ALDH1A1HSD17B10PRKCIFYNHTR1A | |
| SCHEMBL16745261 | 0.80 | MAP2K4 (0.49) | PRKCIFYNHTR1AGPR68HTR7 | |
| SCHEMBL28943563 | 0.80 | PLA2G10 (0.47) | ALDH1A1HSD17B10HTR7 | |
| SCHEMBL5162068 | 0.80 | ALDH1A1 (0.71) | ALDH1A1HSD17B10L3MBTL1ADORA3ADORA2A | |
| SCHEMBL27787239 | 0.79 | ALDH1A1 (0.89) | ALDH1A1HSD17B10L3MBTL1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227366-B2 | Bis-iridium-complexes for manufacturing of ECL-labels | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| EP-2673284-B1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS GMBH (DE) | 2017-08-30 | — | — | EP | disclosed |
| EP-2673283-B1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS GMBH (DE) | 2017-08-23 | — | — | EP | disclosed |
| EP-2882764-B1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS GMBH (DE) | 2017-03-01 | — | — | EP | disclosed |
| EP-2882823-B1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS GMBH (DE) | 2017-02-22 | — | — | EP | disclosed |
| EP-2880042-B1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS GMBH (DE) | 2017-02-01 | — | — | EP | disclosed |
| US-9499573-B2 | Iridium-based complexes for ECL | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499573-B2 | Iridium-based complexes for ECL | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| EP-2880123-B1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS GMBH (DE) | 2016-10-05 | — | — | EP | disclosed |
| EP-2880043-B1 | NEW BIS-IRIDIUM-COMPLEXES FOR MANUFACTURING OF ECL-LABELS | ROCHE DIAGNOSTICS GMBH (DE) | 2016-09-21 | — | — | EP | disclosed |
| WO-2014019710-A1 | NEW BIS-IRIDIUM-COMPLEXES FOR MANUFACTURING OF ECL-LABELS | ROCHE DIAGNOSTICS GMBH (DE) | 2014-02-06 | — | — | WO | disclosed |
| WO-2012107420-A1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS GMBH (DE) | 2012-08-16 | — | — | WO | disclosed |
| WO-2012107419-A1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS GMBH (DE) | 2012-08-16 | — | — | WO | disclosed |
| US-20110315933-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2011-12-29 | — | — | US | disclosed |
| US-20110315933-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2011-12-29 | — | — | US | disclosed |
| US-20110315933-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2011-12-29 | — | — | US | disclosed |
| WO-2010102709-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENCE DEVICES | MERCK PATENT GMBH (DE) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010102709-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENCE DEVICES | MERCK PATENT GMBH (DE) | 2010-09-16 | — | — | WO | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227366-B2 | Bis-iridium-complexes for manufacturing of ECL-labels | HLCS, PDCD2L, LAS1L | ALDH1A1 1757/4885HSD17B10 2722/4885PRKCI 2034/4885 |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | ALDH1A1 4339/4885HSD17B10 1100/4885PRKCI 4454/4885 |
| US-20110315933-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | EPCAM, L1CAM, VCL | ALDH1A1 208/4885HSD17B10 4011/4885PRKCI 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.